"Wellington has proven extremely competent and supportive already prior to the investment. The fact that they have decided to invest in invendo provides further proof for the value of our technology. With the new financing round we will be able to obtain regulatory approval of our invendoscope for the US market – by far the most attractive market in colonoscopy."
Berthold Hackl
CEO, invendo medical
Wellington contact:
Rainer Strohmenger
| The Future of endoscopy |
invendo medical is a developer of an innovative colonoscope (invendoscope™ SC40). With its novel device invendo addresses key deficiencies in one of the largest screening markets in oncology today with more than 20 million colonoscopies being performed every year, thereof 14 million in the US. In contrast to established colonoscopes, invendo’s patented device is sterile and for single use only. The invendoscope™ combines a highly flexible endoscope shaft and the proprietary “inverted sleeve” technology that enables a safer and potentially sedationless colonoscopy, as there are only minimal forces applied against the intestinal wall while the device passes through intestinal convolutions. These advantages should help to further enhance both patient acceptance and procedural efficiency of colonoscopy which has proven to be a highly effective method for prevention of colon cancer.
With the € 4.5 million raised in September 2008 mainly from co-lead investors Wellington Partners and TVM Capital, invendo medical will be able to complete the development of the invendoscope™ through regulatory approval in the US, by far the most attractive market in colonoscopy.
First investment: September 2008
invendo medical GmbH
Peterhofstraße 3b
86438 Kissing
Germany
